Signed in · PRO

Guidance history, every release

Neurocrine Biosciences (NBIX) · 8 releases, Oct 30, 2024 to Jul 30, 2026 · rows are metrics, columns are releases

Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing

Metric	Oct 30, 2024 FY24 Q3	Feb 6, 2025 FY24 Q4	May 5, 2025 FY25 Q1	Jul 30, 2025 FY25 Q2	Oct 28, 2025 FY25 Q3	Feb 11, 2026 FY25 Q4	May 5, 2026 FY26 Q1	Jul 30, 2026 FY26 Q2
For FY2026
INGREZZA® (valbenazine) 2026 Net Sales	—	—	—	—	—	—	—	New“$2.825 to $2.875 Billion”
INGREZZA® (valbenazine) Net Sales	—	—	—	—	—	—	New“$2.7 - $2.8 Billion”	—
GAAP Amortization of Acquired Intangible Assets	—	—	—	—	—	—	—	New“$85 - $90”
GAAP and Non-GAAP IPR&D	—	—	—	—	—	New“$ 20 $ 20”	Reiterated“$20”	—
GAAP R&D	—	—	—	—	—	—	—	New“$1,275 - $1,325”
GAAP R&D Expense	—	—	—	—	—	New“$ 1,200 $ 1,250”	—	—
GAAP SG&A	—	—	—	—	—	—	—	New“$1,575 - $1,600”
GAAP SG&A Expense	—	—	—	—	—	New“$ 1,375 $ 1,400”	—	—
INGREZZA Full Year Net Product Sales	—	—	—	—	—	New“$2.7 - $2.8 Billion”	—	—
INGREZZA Net Product Sales	—	—	—	—	—	New“$ 2,700 $ 2,800”	—	Raised“$2,825 - $2,875”
IPR&D	—	—	—	—	—	—	—	New“$23”
Non-GAAP R&D	—	—	—	—	—	—	—	New“$1,140 - $1,190”
Non-GAAP R&D Expense	—	—	—	—	—	New“$ 1,110 $ 1,160”	—	—
Non-GAAP SG&A	—	—	—	—	—	—	—	New“$1,325 - $1,350”
Non-GAAP SG&A Expense	—	—	—	—	—	New“$ 1,240 $ 1,265”	—	—
R&D development milestones expense	—	—	—	—	—	—	—	New“approximately $25 million”
For FY2025
INGREZZA Net Product Sales	—	New“$2.5 - $2.6 Billion”	Reiterated“$2.5 - $2.6 Billion”	Narrowed“$2.5 - $2.55 Billion”	—	—	—	—
For FY2024
INGREZZA Net Product Sales	New“$2.30 - $2.32 Billion”	—	—	—	—	—	—	—
No period stated
Accelerated Share Repurchase Transaction	New“$300 million”	—	—	—	—	—	—	—
GAAP Amortization of Acquired Intangible Assets	—	—	—	—	—	—	—	New“Not applicable”
GAAP R&D	—	—	—	—	—	—	—	New“$1,200 - $1,250”
GAAP SG&A	—	—	—	—	—	—	—	New“$1,375 - $1,400”
INGREZZA Net Product Sales	—	—	—	—	—	—	—	New“$2,700 - $2,800”
IPR&D	—	—	—	—	—	—	—	New“$20”
Milestone payment to Nxera upon initiation of Phase 3 study for NBI-1117568	New“$15 million”	—	—	—	—	—	—	—
Non-GAAP R&D	—	—	—	—	—	—	—	New“$1,110 - $1,160”
Non-GAAP SG&A	—	—	—	—	—	—	—	New“$1,240 - $1,265”
Remaining Share Repurchase Authorization	—	—	—	New“$332 million”	—	—	—	—
Share Repurchase Authorization	New“$300 Million”	—	—	—	—	—	—	—
Share repurchase program	—	—	New“up to $500 million”	—	—	—	—	—
Share Repurchase Program Authorization	—	—	—	New“up to $500 million”	—	—	—	—

Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.